---
schema_version: "secwatch.filing_event.v1"
accession: "0001274737-22-000067"
form_type: "8-K"
ticker: "XGN"
cik: "0001274737"
company_name: "EXAGEN INC."
filed_at: "2022-10-20T23:59:59+00:00"
generated_at: "2026-06-23T02:12:00.928103+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Exagen names John Aballi CEO, succeeding Ron Rocca who resigned

## Summary
- John Aballi appointed CEO/President and board member effective Oct 16, 2022, replacing Ron Rocca after 11 years.
- Aballi previously SVP/GM Urology and CLIA COO at Veracyte; grew urology unit to $120M+ revenue annually.
- Aballi receives base salary $525,000, target bonus 50% of base, equity award of 350,000 shares/units vesting 4 years.
- Ron Rocca severance: lump sum $424,875, pro-rated incentive compensation, and 9 months COBRA reimbursement.
- Rocca's resignation not due to any disagreement with company's operations, policies, or practices.

## SEC filing metadata
- accession: 0001274737-22-000067
- form_type: 8-K
- ticker: XGN
- cik: 0001274737
- company_name: EXAGEN INC.
- filed_at: 2022-10-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1274737/000127473722000067/0001274737-22-000067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1274737/000127473722000067/exdx-20221016.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001274737-22-000067
- JSON: https://secwatch.observer/filing/0001274737-22-000067.json
- Plain text: https://secwatch.observer/filing/0001274737-22-000067.txt

## Key facts
- Executive change
  Fortunato Ron Rocca resigned as President and Chief Executive Officer at EXAGEN INC..
  - Action: resigned
  - Role: President and Chief Executive Officer
  source text: Fortunato Ron Rocca who resigned as President and Chief Executive Officer of the Company and as a member of the Board of Directors, effective as of October 16, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1274737/000127473722000067/0001274737-22-000067-index.htm
- Executive change
  John Aballi was appointed as President and Chief Executive Officer at EXAGEN INC..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: John Aballi has been appointed as President and Chief Executive Officer of the Company and as a member of the board of directors of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1274737/000127473722000067/0001274737-22-000067-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.